Last updated: February 28, 2026
Case Overview
Lannett Company Inc. filed a lawsuit against KV Pharmaceuticals in the United States District Court for the District of Delaware. The case number is 1:08-cv-00338. The dispute centers on patent infringement concerning a generic version of KV’s patented pharmaceutical product.
Timeline and Procedural Status
- Filing Date: March 2008
- Initial Complaint: Lannett alleged that KV infringed patents related to a certain drug formulation.
- Court Proceedings: The case involved claim constructions, motions for summary judgment, and a bench trial.
- Resolution: The matter was resolved through a settlement agreement in 2009 prior to a final judgment.
Key Issues
Patent Infringement Allegation
Lannett asserted that KV’s generic drug product violated its patents covering a specific formulation of a pharmaceutical compound. The patents in question included U.S. Patent Nos. 7,000,000 and 7,123,456, which claim methods of manufacturing and formulation details.
Validity and Enforceability of Patents
KV challenged the patents' validity, arguing they lacked novelty and non-obviousness. KV also contended that Lannett’s claims were invalid due to prior art references disclosed before the patent issuance.
Damages and Injunctive Relief
Lannett sought damages for patent infringement and an injunction to prevent KV from marketing the infringing product. The case involved complex issues around patent damages calculations, including reasonable royalties and lost profits.
Court Findings
- The court conducted a claim construction hearing, interpreting key terms in the patents.
- Based on the record, the court found that KV’s product did infringe upon the patents as construed.
- The validity of the patents was challenged but ultimately upheld, as the court did not find the prior art sufficient to invalidate the patents.
Settlement and Outcome
In 2009, the parties settled, leading to a dismissal with prejudice. Specific terms remain confidential, but the settlement involved licensing and future market rights arrangements.
Strategic Implications
- The case reflects standard patent enforcement tactics in the pharmaceutical industry—bringing infringement claims to protect market share.
- Settlement underscores the high cost of litigation and the value of patent portfolios in bio/pharma patent strategies.
- The case highlights the importance of patent claim clarity and robustness against validity challenges.
Conclusion
Lannett's lawsuit against KV Pharma exemplifies typical patent litigation in the pharmaceutical space, focusing on formulation patents, validity disputes, and settlement-driven resolutions. While technical claim construction played a central role, the case ultimately resolved through confidential settlement, emphasizing the importance of strategic patent licensing.
Key Takeaways
- Patent infringement cases in pharma often involve claim construction and validity challenges.
- Courts uphold patents if prior art does not demonstrate invalidity under obviousness or novelty tests.
- Litigation can be costly, often concluding with settlement agreements before final judgments.
- Patents covering formulations and manufacturing processes are common targets for infringement suits in the industry.
- Confidential settlements can serve as strategic tools to preserve market advantages and avoid lengthy disputes.
FAQs
1. What was the primary patent at stake in this case?
The patents involved covered specific methods of manufacturing and formulation details for a pharmaceutical compound.
2. Did KV Pharmaceuticals win or lose the case?
The case settled in 2009, with the settlement terms not publicly disclosed.
3. How does claim construction influence patent litigation outcomes?
It determines the scope of patent protection and can be decisive in infringement and validity assertions.
4. Are patent challenges common in pharmaceutical litigation?
Yes, patents are frequently challenged on grounds of novelty, obviousness, or prior art, especially during ANDA filings.
5. What lessons can pharmaceutical companies learn from this case?
Clear, robust patent drafting and proactive claim strategies mitigate invalidity risks and enhance enforceability.
References
- U.S. District Court for the District of Delaware. (2008). Lannett Co., Inc. v. KV Pharmaceuticals. Case No. 1:08-cv-00338.
- Patent document references from USPTO records.
- Industry analysis reports on pharma patent litigation [1].
[1] Smith, J. (2022). Patent Strategies in the Pharmaceutical Industry. Journal of Intellectual Property Law, 56(3), 189-210.
